Synchronous filtering method for improving the optical signal-to-noise ratio of a tunable laser based on the Fabry-Pérot interferometer.

Optical measurements are closely related to the optical signal-to-noise ratio (OSNR) of the laser, which can be improved using a tunable optical filter (TOF) to suppress frequency noise. For an external-cavity tunable laser with a tuning range larger than the TOF bandwidth, the wavelength at the center of the TOF passband must be varied based on the laser tuning. This study proposes a tunable-laser OSNR-enhancement method based on the Fabry-Pérot (FP) interferometer. The FP signal contains the wavelength information of the swept laser, which can be used to determine the real-time driving voltage of the TOF. Notably, the laser needs to be continuously tunable without mode hopping, and the free spectral range of the FP interferometer must be smaller than the TOF bandwidth.

Truncated Diphtheria Toxin DT390 Enhances the Humoral Immunogenicity of Porcine Circovirus Type 2 Capsid Antigen in Mice.

Porcine circovirus type 2 (PCV2) is the causative agent of PCV-associated disease, which harms the swine industry worldwide. Open reading frame 2 of PCV2 encodes the principal immunogenic capsid (Cap) protein, which induces neutralizing antibodies and protective immunity. Cap has been developed as a subunit vaccine against PCV2 infection, although its use is hindered by low immunogenicity. Here, we hypothesized that the truncated diphtheria toxin DT390 might enhance the immunogenicity of Cap. To verify this hypothesis, we fused Cap with DT390, which was expressed using the unique diphtheria toxin-resistant Pichia pastoris expression system. We assessed the immunogenicity of DT390-Cap using BALB/c mice. DT390-Cap induced significantly higher Cap-specific and neutralizing antibodies than Cap alone with or without the ISA201 adjuvant. DT390-Cap with ISA201 adjuvant induced production of more Cap-specific antibodies and neutralizing antibodies than Ingelvac CircoFLEX (positive control). DT390-Cap induced slightly higher Th2-associated interleukin-4 production than Cap alone but did not affect Th1-associated interferon-γ production. The protection study demonstrated that DT390-Cap induced more effective protective immunity than Cap alone, when challenged with PCV2. The viral loads in the lungs, liver, and thymus in mice immunized using DT390-Cap were significantly lower than in those immunized with the corresponding Cap with or without the ISA201 adjuvant. Taken together, the engineered DT390 effectively enhanced the immunogenicity and protective immunity of Cap in mice. Thus, DT390-Cap is a promising novel vaccine candidate against PCV2 infection.